Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
Zealthy helps with submitting prior authorizations for Ozempic, Mounjaro, Wegovy, and Zepbound
Lilly releases Zepbound (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Image INDIANAPOLIS- Eli Lilly and Company (NYSE: LLY) today announced Zepbound (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand
Best fit Maximum weight-loss potential Outcome signal Up to 22.5% mean loss Evidence cue SURMOUNT evidence Decision rhythm Week 1 / Weeks 4-8 / Months 3-6 Best-fit signals Choose Compounded Tirzepatide when these match your goal Maximum weight-loss potential Decision timeline What to expect as you compare Compounded Tirzepatide Timelines vary by goal, dose, baseline health, and consistency
District Court for the District of Louisiana on August 2, 2023
US$ 22.70
US$ 28.57
US$ 25.01
